# Efficacy, Safety, Tolerability, and Biomarkers of Ibudilast (MN-166) in Patients Hospitalized With COVID-19 at Risk for ARDS

> **NCT04429555** · PHASE2 · COMPLETED · sponsor: **MediciNova** · enrollment: 34 (actual)

## Conditions studied

- Pneumonia, Viral

## Interventions

- **DRUG:** Ibudilast
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04429555
- **Lead sponsor:** MediciNova
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-01-11
- **Primary completion:** 2022-06-30
- **Final completion:** 2024-08-07
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2024-10-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04429555

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04429555, "Efficacy, Safety, Tolerability, and Biomarkers of Ibudilast (MN-166) in Patients Hospitalized With COVID-19 at Risk for ARDS". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT04429555. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*